Clinical, epidemiological, and laboratory studies suggest that cholesterol may play a role in the pathogenesis of Alzheimer's disease (AD). Transgenic mice exhibiting an Alzheimer's ␤-amyloid phenotype were treated with the cholesterol-lowering drug BM15.766 and tested for modulation of ␤-amyloid levels. BM15.766 treatment reduced plasma cholesterol, brain A␤ peptides, and ␤-amyloid load by greater than twofold. A strong, positive correlation between the amount of plasma cholesterol and A␤ was observed. Furthermore, drug treatment reduced the amyloidogenic processing of the amyloid precursor protein, suggesting alterations in processing in response to cholesterol modulation. This study demonstrates that hypocholesterolemia is associated with reduced A␤ accumulation suggesting that lowering cholesterol by pharmacological means may be an effective approach for reducing the risk of developing AD.
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the deterioration of cognitive function and behavioral changes (Hardy, 1997; Mattson, 1997) . A major neuropathological feature of AD is the neuritic plaque which, in addition to other components, is composed primarily of insoluble ␤-amyloid fibrils of a 40-to 42-amino-acid peptide known as the amyloid ␤ peptide (A␤) (Mattson, 1997; Gandy, 1999) . A␤ peptides are proteolytically derived, by the action of ␤-and ␥-secretase activities, from a large precursor protein known as the amyloid precursor protein (APP) (Gandy, 1999) . In addition, APP is cleaved by ␣-secretase activities, producing sAPP␣, which precludes A␤ formation (Gandy, 1999) . Recent studies have shown that increased levels of A␤ peptides are among the earliest detectable abnormalities in the pathophysiology of AD and may mediate downstream events leading to neuronal degeneration and cognitive decline (Hardy, 1997; Mattson, 1997; Gandy, 1999) .
There is increasing evidence, from clinical, epidemiological, and laboratory studies, suggesting that cholesterol plays a role in the pathogenesis of AD (Jarvik et al., 1994; Sparks et al., 1994; Jarvik et al., 1995; Bodovitz & Klein, 1996; Kalmijin et al., 1997; Howland et al., 1998; Mizuno et al., 1998; Simons et al., 1998; Frears et al., 1999; Grant, 1999; Roher et al., 1999; Wood et al., 1999; Jick et al., 2000; Refolo et al., 2000; Sparks et al., 2000; Wolozin et al., 2000; Fassbender et al., 2001) . Among these are several clinical and epidemiological studies suggesting that elderly individuals with elevated plasma cholesterol have increased susceptibility
